Status
Conditions
Treatments
About
The main objective of this study : Demonstrate that GBS (group B streptococci) "ST-17" colonize and persist to 60 days twice in the digestive tract of newborns that strains of GBS non-ST-17.
Secondary objectives:Determine:
Full description
Women tested positive for GBS during systematic vaginal screening at 35-37 weeks, will be proposed to participate to the study and will be included after reading the information letter and signature the consent form.
INCLUSION (D0 at time of delivery)
In the labor ward, two women's groups 1 and 2:
Group 1 = Women tested positive for GBS pre-selected and included in the protocol (see pre-inclusion) Group 2 = Women without antenatal vaginal screening and at risk of neonatal infection.
For both groups, at time of delivery:
At the beginning of the labour performed vaginal swabs (PV0):
For all women included (Group 1 and Group 2 women with a positive GBS vaginal sample) will be achieved in the delivery room:
For mothers, the collection of 3-5 ml of milk when breastfeeding.
Monitoring schedule:
Day 21 and day 60 post delivery:
the following samples for search of GBS for will be performed to gather the primary endpoint:
For the mother:
For the newborn:
Processing bacteriological samples:
All samples will be subjected to bacteriological analysis and DNA extraction for detection of GBS. GBS isolated will be identified and stored at - 80 ° C in a declared biological collection. DNA extracts will also stored at -20 ° C in a declared biological collection. All samples for microbiological analysis will be stored at - 80 ° C.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
- Patient does not speak and does not understand French
Primary purpose
Allocation
Interventional model
Masking
949 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal